Background: The efficacy of montelukast (MONT), a cysteinyl leukotriene receptor antagonist, in nonasthmatic eosinophilic bronchitis (NAEB), especially its influence on cough associated life quality is still indefinite.
Nonasthmatic eosinophilic bronchitis (NAEB), which was first identified by Gibson et al .
Acute cough typically lasts fewer than three weeks, and although it can be associated with life-threatening illnesses--such as pneumonia, HE or pulmonary embolism--it is typically caused by one of four main disease processes: upper airway cough syndrome (UACS), asthma, GERD, or nonasthmatic eosinophilic bronchitis
Nonasthmatic eosinophilic bronchitis is generally not as common as GERD, but it remains a common cause of chronic cough.
If chronic cough persists despite following these measures, nonasthmatic eosinophilic bronchitis should be considered.